CRP指导抗生素疗程、7天疗程或14天疗程对无并发症革兰阴性菌血症30天临床失败率的影响:一项随机临床试验
该多中心非劣效随机试验纳入504例无并发症革兰阴性菌血症成人患者,比较CRP指导、固定7天和固定14天抗生素疗程的30天临床失败率。结果显示CRP指导组和7天组30天失败率非劣效于14天组,但非劣效界值大、事件率低,且CRP组依从性低、疗程范围宽,解释受限。
要点
- CRP指导组30天临床失败率为2.4%,7天组6.6%,14天组5.5%。
- CRP指导组和7天组30天失败率非劣效于14天组(非劣效界值10%)。
- CRP组中位抗生素疗程为7天(IQR 6-10),21%完成30天随访者存在方案违背。
核心结论
- 在无并发症革兰阴性菌血症成人中,CRP指导抗生素疗程和固定7天疗程的30天临床失败率非劣效于固定14天疗程。
- 但解释受限于较大的非劣效界值(10%)、较低的事件率、CRP组低依从性及宽泛的疗程范围。
研究设计与样本
- 多中心、非劣效、床旁随机临床试验,于2017年4月至2019年5月在3家瑞士三级医院进行,随访至2019年8月。
- 纳入成人(≥18岁)因发酵革兰阴性菌血症住院、经微生物有效治疗第5天(±1天)、无发热24小时且无复杂感染或严重免疫抑制证据者。
- 按1:1:1随机分为CRP指导组(n=170)、固定7天组(n=169)和固定14天组(n=165)。
主要发现
- 共504例患者随机(中位年龄79岁,IQR 68-86;女性306/503,61%),493例(98%)完成30天随访,448例(89%)完成90天随访。
- 30天主要结局(临床失败)发生率:CRP组4/164(2.4%),7天组11/166(6.6%),14天组9/163(5.5%)。
- CRP组 vs 14天组差异为-3.1%(单侧97.5%CI,-∞至1.1;P<.001);7天组 vs 14天组差异为1.1%(单侧97.5%CI,-∞至6.3;P<.001)。
- 90天临床失败:CRP组10/143(7.0%),7天组16/151(10.6%),14天组16/153(10.5%)。
- CRP组中位抗生素疗程为7天(IQR 6-10;范围5-28天);完成30天随访的164例中34例(21%)存在与治疗分配相关的方案违背。
关键数值与推荐
- 非劣效界值为10%。
- 主要结局为30天临床失败率,定义为复发菌血症、局部化脓性并发症、远处并发症(同一病原体生长)、因怀疑初始病原体导致临床恶化而重启革兰阴性菌导向抗生素治疗或全因死亡中至少一项。
临床怎么用
- 对于无并发症革兰阴性菌血症成人,可考虑将抗生素疗程缩短至7天或采用CRP指导的疗程。
- 应用CRP指导策略时需注意其依从性可能较低且疗程范围较宽,应结合临床判断。
局限性
- 非劣效界值(10%)相对于观察到的低事件率较大。
- CRP指导组方案违背率较高(21%),且疗程范围宽(5-28天)。
- 30天和90天随访完成率分别为98%和89%,存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antibiotic overuse drives antibiotic resistance. Gram-negative bacteremia is a common infection that results in substantial antibiotic use. OBJECTIVE: To compare the clinical effectiveness of C-reactive protein (CRP)-guided, 7-day, and 14-day antibiotic durations 30, 60, and 90 days after treatment initiation. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, noninferiority, point-of-care randomized clinical trial including adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary care hospitals between April 2017 and May 2019, with follow-up until August 2019. Patients and physicians were blinded between randomization and antibiotic discontinuation. Adults (aged ≥18 years) were eligible for randomization on day 5 (±1 d) of microbiologically efficacious therapy for fermenting, gram-negative bacteria in blood culture(s) if they were afebrile for 24 hours without evidence for complicated infection (eg, abscess) or severe immunosuppression. INTERVENTION: Randomization in a 1:1:1 ratio to an individualized CRP-guided antibiotic treatment duration (discontinuation once CRP declined by 75% from peak; n = 170), fixed 7-day treatment duration (n = 169), or fixed 14-day treatment duration (n = 165). MAIN OUTCOMES AND MEASURES: The primary outcome was the clinical failure rate at day 30, defined as the presence of at least 1 of the following, with a non-inferiority margin of 10%: recurrent bacteremia, local suppurative complication, distant complication (growth of the same organism causing the initial bacteremia), restarting gram-negative-directed antibiotic therapy due to clinical worsening suspected to be due to the initial organism, or death due to any cause. Secondary outcomes included the clinical failure rate on day 90 of follow-up. RESULTS: Among 504 patients randomized (median [interquartile range] age, 79 [68-86] years; 306 of 503 [61%] were women), 493 (98%) completed 30-day follow-up and 448 (89%) completed 90-day follow-up. Median antibiotic duration in the CRP group was 7 (interquartile range, 6-10; range, 5-28) days; 34 of the 164 patients (21%) who completed the 30-day follow-up had protocol violations related to treatment assignment. The primary outcome occurred in 4 of 164 (2.4%) patients in the CRP group, 11 of 166 (6.6%) in the 7-day group, and 9 of 163 (5.5%) in the 14-day group (difference in CRP vs 14-day group, -3.1% [1-sided 97.5% CI, -∞ to 1.1]; P < .001; difference in 7-day vs 14-day group, 1.1% [1-sided 97.5% CI, -∞ to 6.3]; P < .001). By day 90, clinical failure occurred in 10 of 143 patients (7.0%) in the CRP group, 16 of 151 (10.6%) in the 7-day group, and 16 of 153 (10.5%) in the 14-day group. CONCLUSIONS AND RELEVANCE: Among adults with uncomplicated gram-negative bacteremia, 30-day rates of clinical failure for CRP-guided antibiotic treatment duration and fixed 7-day treatment were noninferior to fixed 14-day treatment. However, interpretation is limited by the large noninferiority margin compared with the low observed event rate, as well as low adherence and wide range of treatment durations in the CRP-guided group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03101072.
引用
- von Dach E, Albrich WC, Brunel AS, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020. PMID: 32484534. doi:10.1001/jama.2020.6348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。